Effects of Bolus and Continuous Nasogastric Feeding on Small Bowel Water Content and Blood Flow

Sponsor
University of Nottingham (Other)
Overall Status
Completed
CT.gov ID
NCT01557673
Collaborator
(none)
12
1
2
11
1.1

Study Details

Study Description

Brief Summary

Following surgery some patients are unable to swallow. For those requiring nutritional support a tube is sometimes passed through the nose into the stomach to provide feeding. Traditionally this type of feeding is given slowly over the course of the day. However, it is thought that this mode of feeding might increase the amount of fluid entering the bowel contributing to symptoms of diarrhoea. An alternative strategy of feeding, given in larger volumes in a shorter space of time resembles normal feeding patterns and may reduce the amount of water entering the bowel.

In this study we want to use a non invasive medical imaging technique called "magnetic resonance imaging" (or MRI) to look at the volume of bowel water following these two feeding strategies in 12 healthy volunteers.

Each volunteer will have a tube inserted into the stomach via the nose and undergo the two feeding strategies at least 7 days apart. We will take repeated images using the MRI scanner to assess the bowel response and some samples of blood are required for analysis of blood sugar.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: NG bolus feeding over 5 min
  • Dietary Supplement: Continuous NG feeding over 4 h
Phase 1/Phase 2

Detailed Description

  1. Background. Nutritional support is often required for undernourished patients who are unable to meet daily nutritional requirements. This is often due to lack of consciousness or problems with swallowing, Nasogastric (NG) feeding is often employed to provide active enteric nutritional support. The current approach for delivering this support usually involves pump-assisted continuous feeding spread throughout the course of a day. However, this practice is far from physiological and may promote excessive secretion of fluid into the small bowel, contributing to gastrointestinal symptoms frequently experienced by NG fed patients. Rarely, continuous enteral tube feeding has been associated with small bowel ischaemia or necrosis, although this observation has almost always been made in the critically ill. Bolus feeds given in larger volumes over shorter time periods replicate the pattern of normal feeding. Consequently gastric emptying using this method is slowed and may, therefore, reduce the metabolic demand on the small intestine and prevent excessive accumulation of small bowel fluid.

  2. Aims. This study aims to investigate the influence of bolus or continuous NG feeding on small bowel fluid content and superior mesenteric blood flow. Our hypothesis is that bolus NG feeding results in lower small bowel fluid secretion and a reduction in superior mesenteric artery blood flow in comparison to individuals who are bolus NG fed.

  3. Experimental protocol and methods.

This is a single-centre, cross-over study involving 12 healthy volunteers. Two studies will be undertaken for each volunteer approximately 7 days apart:

  • Tube bolus (TB): feed administered via the NG tube over 5 min.

  • Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.

The sequence of treatment allocations will be concealed to assessors until all interventions, data collection, and statistical analysis has been completed.

Subjects will be asked to arrive at 8:30 a.m. at the Sir Peter Mansfield Magnetic Resonance 1.5T, University of Nottingham, having abstained from alcohol, caffeine-containing drinks, and any medication for at least 24 h prior to the study, as well as having fasted overnight. An 80 cm 8FR Freka (Fresenius Kabi, Runcorn, UK) fine bore nasogastric (NG) tube will be inserted into the stomach via the nose as well as a cannula in the ante cubital fossa for blood sampling. The position of the NG tube will be verified by magnetic resonance imaging (MRI). Once the tube is sited, the volunteer will be asked to sit for 5 min in order to allow the tubes to settle and the body adapt to their presence. Following NG intubation subjects will undergo baseline MRI scanning and blood sampling for glucose, insulin and PYY. Feeding will commence at time 0. Scanning and blood tests will proceed at 30 min intervals for a total of 4 h. The feed used in all studies will be 400 ml of Resource® Energy Vanilla nutrient drink (Nestle Nutrition, Société des Produits Nestlé S.A), which is typical of a standard oral supplement.

In the TB study arm the supplement will be administered through the NG tube via syringes over 5 min; and in the TD study the feed will be administered using a pump at a rate of 100 ml/h for 4 h.

  1. Measurable end points/statistical power of the study. Primary endpoint: Small bowel water content (SBWC). Secondary endpoints: Superior mesenteric artery blood flow, gastric content emptying time, plasma concentrations of glucose, insulin and peptide YY (PYY). Previous work using mannitol and glucose indicates that mean (SD) SBWC at 40 minutes postprandially after ingesting 300ml glucose was 47 (SD 15) and using n=10 we calculate we can detect a difference of 17 ml (36%) between interventions with 90% power. We plan to recruit 12 to allow for dropouts.

Study Design

Study Type:
Interventional
Actual Enrollment :
12 participants
Allocation:
Non-Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effects of Bolus and Continuous Nasogastric Feeding on Small Bowel Water Content and Blood Flow
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Dec 1, 2012
Actual Study Completion Date :
Dec 1, 2012

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: NG bolus feeding over 5 min

Tube bolus (TB): feed administered via syringe through NG tube over 5 min.

Dietary Supplement: NG bolus feeding over 5 min
Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
Other Names:
  • Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A
  • Placebo Comparator: Continuous NG feeding over 4 h

    Continuous tube drip feeding (TD): feed pump delivered via the NG tube over 4 h.

    Dietary Supplement: Continuous NG feeding over 4 h
    Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
    Other Names:
  • Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A
  • Outcome Measures

    Primary Outcome Measures

    1. Small bowel water volume (ml) [0-240 min]

      Small bowel water content assessed by magnetic resonance imaging.

    Secondary Outcome Measures

    1. Gastric emptying [0-240 min]

      Gastric volume assessed by magnetic resonance imaging.

    2. Superior mesenteric artery blood flow [0-240 min]

      Superior mesenteric artery blood flow and velocity assessed by magnetic resonance imaging.

    3. Peptide YY [0-240 min]

      Serum concentration of peptide YY

    4. Insulin [0-240 min]

      Serum concentration of insulin

    5. Glucose [0-240 min]

      Serum concentration of glucose

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 65 Years
    Sexes Eligible for Study:
    Male
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Healthy

    • Male

    • Able to undergo safe magnetic resonance scanning

    Exclusion Criteria:
    • Female

    • Chronic medical conditions

    • Regular medication

    • Unable to undergo safe magentic resonance scanning

    • Previous abdominal surgery

    • Smoking

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Sir Peter Mansfield Magnetic Resonance Centre Nottingham Nottinghamshire United Kingdom NG7 2RD

    Sponsors and Collaborators

    • University of Nottingham

    Investigators

    • Principal Investigator: Abeed H Chowdhury, BSc MRCS, University of Nottingham
    • Study Chair: Tim Bowling, MD FRCP, Nottingham University Hospitals NHS Trust

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University of Nottingham
    ClinicalTrials.gov Identifier:
    NCT01557673
    Other Study ID Numbers:
    • H062011
    First Posted:
    Mar 19, 2012
    Last Update Posted:
    May 6, 2013
    Last Verified:
    May 1, 2013
    Keywords provided by University of Nottingham
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 6, 2013